Akums Drugs and Pharmaceuticals
- Market cap
- ₹ 10,640 Cr.
- P/E
- 37.3x
- P/B
- 3.14x
- 52-week range
- 409.3 – 838.8
- ROE
- 8%
- ROCE
- 15%
- Dividend yield
- 0.2%
- Debt / equity
- 0.05
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Pharmaceuticals
- Listed on
- NSE, BSE
About
Akums Drugs and Pharmaceuticals Limited is an India-based pharmaceutical contract development and manufacturing company. The Company offers a comprehensive range of pharmaceutical products and services in India and overseas. The Company’s segments include Contract Development and Manufacturing Operations (CDMO), Active Pharmaceutical Ingredient (API), Domestic Branded Formulations, International Branded Formulations, and Trade Generics. The CDMO segment is engaged in formulation research and development, preparation and regulatory filing of dossiers, manufacturing formulations on a contract basis, job work and testing services. The API segment is engaged in the manufacture and sale of key starting materials, Intermediate and API products. The Domestic Branded Formulations segment includes marketing of its branded formulations in the Indian market. The International Branded Formulations segment undertakes the marketing of its branded formulations in the global market.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Pharmaceuticals: 221 companies →Akums Drugs and Pharmaceuticals against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)37.3 against a typical 34.3: pricier than most peers (1st = cheapest).123rd of 220
- Sales growth+14% against a typical +15.6% from a year earlier.105th of 197
- Profit growth+55.4% against a typical +18.9% from a year earlier.49th of 160
- Share price, 3 months+12.3% against a typical 0%.57th of 200
- Size₹ 10,639.8 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).40th of 199
Credit ratings
Every rating action on file, newest first, including reaffirmations. Open a row for the agency's reasoning. All credit rating updates
High safety
Rated AA by ICRA- No warnings from the agency.
| Agency | Current rating | Outlook | As of |
|---|---|---|---|
| ICRA | [ICRA]AA /[ICRA]A1+ | Stable | 10 Apr 2026 |
| Rating | Details | |||||
|---|---|---|---|---|---|---|
| 10 Apr 2026 | New rating | [ICRA]AA /[ICRA]A1+ | — | ICRA | ₹ 285 Cr. |
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 2 Nov 2026Upcoming | Financial Results | To consider and approve the un-audited (Standalone & Consolidated) financial results for the quarter and half year ended on September 30, 2026 |
| 8 Aug 2026 | Financial Results | Intimation of Board Meeting |
| 14 May 2026 | Financial Results | Board Meeting Intimation for approval of the audited (Standalone & Consolidated) Financial Results for the quarter and financial year ended on 31st March, 2026. |
| 13 Feb 2026 | Financial Results | To consider and approve the financial results for the period ended December 31, 2025 |
| 13 Nov 2025 | Financial Results | To consider and approve the financial results for the period ended September 30, 2025 |
| 8 Aug 2025 | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2025 |
| 26 May 2025 | Financial Results | To consider and approve the Un-audited (Standalone & Consolidated) Financial Results for the quarter ended on 31st March, 2025 and Audited (Standalone & Consolidated) Financial statements for the year ended on 31st March, 2025 |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,181 | 1,083 | 944 | 1,019 | 1,033 | 1,010 | 1,056 | 1,024 | 1,018 | 1,160 | 1,158 | 1,167 |
| Expenses | 1,029 | 989 | 941 | 891 | 912 | 889 | 962 | 895 | 923 | 1,013 | 1,006 | 992 |
| Operating Profit | 152 | 93 | 3 | 128 | 121 | 121 | 94 | 129 | 94 | 147 | 152 | 175 |
| OPM % | 13% | 9% | 0.3% | 13% | 12% | 12% | 9% | 13% | 9% | 13% | 13% | 15% |
| Other Income | −21 | 10 | 10 | 7 | 17 | 19 | 26 | 27 | 32 | 16 | 34 | 30 |
| Interest | 14 | 12 | 12 | 13 | 12 | 5 | 5 | 23 | 23 | 24 | 24 | 25 |
| Depreciation | 30 | 32 | 34 | 34 | 35 | 45 | 40 | 37 | 38 | 40 | 40 | 41 |
| Profit before tax | 87 | 59 | −33 | 87 | 92 | 91 | 75 | 96 | 66 | 100 | 121 | 139 |
| Tax % | 62% | −229% | 20% | 30% | 27% | 27% | −99% | 32% | 35% | 32% | 33% | 27% |
| Net Profit | 33 | 195 | −39 | 61 | 67 | 66 | 150 | 65 | 43 | 68 | 81 | 101 |
| EPS in Rs | 2.22 | 13.54 | −2.89 | 4.08 | 4.14 | 4.14 | 9.38 | 4.03 | 2.59 | 4.21 | 5.38 | 6.35 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- 10%
- 5 Years
- 10%
- 3 Years
- 6%
- TTM
- 9%
- 10 Years
- 16%
- 5 Years
- 16%
- 3 Years
- 29%
- TTM
- −7%
- 10 Years
- —
- 5 Years
- —
- 3 Years
- —
- TTM
- —
- 10 Years
- —
- 5 Years
- 6%
- 3 Years
- 10%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Akums Drugs and Pharmaceuticals | ₹ 741.55 | ₹ 10,640 Cr. | 37.3x | 3.1x | 8% | — |
| Sun Pharmaceutical Industries | ₹ 1,743.00 | ₹ 4,18,194 Cr. | 38.4x | 5.6x | 14.2% | 19.1% |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 73.3x | 11.5x | 16.2% | 24.3% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 72.7x | 19.2x | 27.1% | 15.3% |
| Cipla | ₹ 1,337.00 | ₹ 1,08,011 Cr. | 27.6x | 3.3x | 11.8% | 13.7% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 21.2x | 4.2x | 19.7% | 18.5% |
Management
- Sumeet Sood
- Chief Financial Officer
- Dharamvir Malik
- Compliance Officer, Company Secretary
- Sandeep Jain
- Managing Director and Co-Founder, Executive Director
- Sanjeev Jain
- Managing Director and Co-Founder, Executive Director
- Sanjay Kumar Sinha
- Whole Time Director, President - Operations
Prices are delayed and for information only. Nothing on this page is investment advice.